Physician profile
Brian Matthys
NPI 1982631172
$4,840.55
in general payments reported to CMS, 2019-2025
30 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $109 · 2021: $215 · 2022: $384 · 2023: $1,281 · 2024: $1,182 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,203.03 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,012.75 | 2019-2025 | |
| Pfizer INC. | $516.50 | 2019-2025 | |
| Janssen Biotech, INC. | $373.94 | 2019-2025 | Tremfya |
| Dermavant Sciences, INC. | $328.69 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $293.92 | 2019-2025 | Aklief, Epsolay, Twyneo |
| E.R. Squibb & Sons, L.L.C. | $275.15 | 2023-2025 | Sotyktu |
| Ucb, INC. | $267.90 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $260.90 | 2021-2025 | Winlevi |
| Novartis Pharmaceuticals Corporation | $211.91 | 2019-2025 | |
| Leo Pharma INC. | $181.56 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $177.79 | 2022-2025 | Opzelura |
| Amgen INC. | $111.26 | 2023-2025 | Otezla, Otezla |
| Allergan, INC. | $99.18 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $95.09 | 2019-2025 | Dupixent, Libtayo |
| Fresenius Kabi USA, LLC | $85.33 | 2023 | Idacio |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $74.84 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Integra Lifesciences Corporation | $64.91 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Genzyme Corporation | $63.92 | 2023-2025 | |
| Genentech USA, INC. | $57.75 | 2019-2024 | Erivedge |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.91 | 2019-2024 | Cabtreo |
| Almirall LLC | $41.57 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $36.04 | 2019-2023 | |
| Strata Skin Sciences, INC. | $28.15 | 2019-2025 | Xtrac |
| Arcutis Biotherapeutics, INC. | $27.78 | 2024-2025 | Zoryve |
| Biofrontera INC. | $23.01 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.62 | 2024 | Tremfya |
| Organon LLC | $17.29 | 2024 | |
| Celgene Corporation | $15.01 | 2019 | |
| Journey Medical Corporation | $14.23 | 2019 | |
| Dermira, INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Matthys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.